Accumulating evidence shows that β2-AR signaling contributes to the progression and therapy resistance of prostate cancer via regulating trans-differentiation of cancer cells to neuroendocrine-like cells and thus affecting apoptosis, angiogenesis, epithelial-mesenchymal transition, migration, and metastasis. Here, ADRB2 is linked to prostate carcinoma.